Publicaciones en las que colabora con Carlos Panizo Santos (12)

2020

  1. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073

2019

  1. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2017

  1. A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates

    Journal of Immunological Methods, Vol. 442, pp. 54-58

  2. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

2016

  1. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity

    Immunologic Research, Vol. 64, Núm. 2, pp. 548-557

2010

  1. Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease

    Haematologica

2009

  1. Prolonged idiotypic vaccination against follicular lymphoma

    Leukemia and Lymphoma, Vol. 50, Núm. 1, pp. 47-53

  2. Splenic marginal zone lymphoma with Evans' syndrome, autoimmunity, and peripheral gamma/delta T cells

    Annals of Hematology

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

2004

  1. Past, present and future of anti-idiotype vaccination

    Revista de medicina de la Universidad de Navarra, Vol. 48, Núm. 3, pp. 14-23

2003

  1. Estrategias terapéuticas con vacunas idiotípicas en el tratamiento del linfoma folicular

    Hematologia - Citocinas, Inmunoterapia y Terapia Celular, Vol. 6, Núm. 3, pp. 175-182

  2. Feasibility of idiotype vaccination in relapsed B-cell malignancies

    Haematologica, Vol. 88, Núm. 12, pp. 1438-1440